NFS Leasing signs $1 million healthcare agreement

Kevin Richardson, chief executive officer of Sanuwave, said: “The agreement with NFS is a crucial announcement for the company as we execute our plan for a successful rollout in the massive US diabetic foot ulcer (DFU) market.  This allows us to access capital to place devices which in turn will drive procedures and ultimately revenue.”

The company aims to ship its dermaPACE system to clinicians and wound care centers across the US throughout 2018, now that it has achieved the necessary Food and Drug Administration (FDA) clearance.

David DePamphilis, chief operating officer of NFS Leasing (pictured above), said: “We have been following Sanuwave’s progress for a while and began discussions about doing business together prior to their good news from the FDA.

“We are glad to be providing capital for a business model that will help heal a massive medical problem involving diabetic foot ulcers. The company has developed a great go to market strategy and we are looking forward to a successful strategic relationship.”